SecBot SecBot

CBIO

CRESCENT BIOPHARMA, INC.
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001253689 Biotech & Drug Discovery
$12.76 −0.06 (−0.47%)
Oct 26 4:00 PM ET · prev $12.82
Market cap
$476.2M
Small cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
$31.50
+147% · range $27.00–36.00
Next earnings
Nov 4
in 8 days
1 year
+2.1%
from $12.50 · Oct 28
30 days
−12.2%
from $14.53
52-week range
$8.94–26.98
−53% from high · low Feb 13
Avg volume 20D
331.4K
Oct 7 spike 1.05M
Short interest
4.42M
≈11.9% of shares · −7.5%
Days to cover
12.7
at average volume
Insider net
+$18.5M
1 buyer · 7 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 4, 2026
Strongest NEUTRAL Crescent Biopharma provided a clinical pipeline update, highlighting completion of dose escalation in the…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $20.0M at an average $14.50. 7 insiders sold $1.5M. Price is 12% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 9 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −7.5% to 4.42M shares. 12.7 days to cover, ≈11.9% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,271,762$22.9M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED384,576$6.9M
JENNISON ASSOCIATES LLCDOUBLED378,507$6.8M
STATE STREET CORPDOUBLED315,587$5.7M
UBS Group AGDOUBLED175,182$3.2M
NORTHERN TRUST CORPDOUBLED138,778$2.5M
Woodline Partners LPADD94,488$1.7M
VANGUARD FIDUCIARY TRUST COADD75,225$1.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy5Buy7Hold2Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +147%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 6, 2026HC Wainwright & Co.
UPGRADE
UPGRADEBuy
Sep 14, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 27, 2026Wedbush
REITERATE
REITERATEOutperform
Jun 1, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$20.0M
bought · 1 insider
$1.5M
sold · 7 insiders
−12.0%
vs their $14.50 cost
DateInsiderTypeValue
Sep 18, 2026
McNeill Jonathan
President and COO
SELL$64.1K
Sep 18, 2026
Brumm Joshua T
Chief Executive Officer
SELL$131.0K
Sep 16, 2026
Brumm Joshua T
Chief Executive Officer
SELL$28.8K
Sep 16, 2026
Pinkas Jan
Chief Scientific Officer
SELL$11.8K
Sep 16, 2026
McNeill Jonathan
President and COO
SELL$13.1K
Sep 16, 2026
Bispham Barbara Harlin
See Remarks
SELL$11.1K
Sep 16, 2026
Scalzo Richard William
Chief Financial Officer
SELL$10.2K
Sep 16, 2026
Im Ellie Eunkyung
Chief Medical Officer
SELL$11.2K

Earnings setup

Estimates
Nov 4
reports in 8 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
4,419,185
shares short
-7.5%
vs prior settlement
12.7
days to cover
≈11.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Crescent Biopharma provided a clinical pipeline update via an 8-K, announcing that the Phase 1/2 ASCEND trial of…
8-K — Impact 3/10
Oct 15, 2026 Press
Crescent Biopharma provided a clinical pipeline update, highlighting completion of dose escalation in the global Phase…
Impact 4/10
Oct 15, 2026 FDA
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escala
Oct 5, 2026 Press
Crescent Biopharma announced FDA clearance of its IND application for CR-002, a topoisomerase inhibitor ADC targeting…
Impact 4/10
Sep 18, 2026 SEC
CEO Joshua Brumm and President/COO Jonathan McNeill sold a combined $195K of CBIO stock on September 18, 2026, at…
CLUSTER — Impact 3/10
Sep 18, 2026 Insider
McNeill Jonathan sold 3,839 shares
President and COO @ $16.71 ($64.1K)
Sep 18, 2026 Insider
Brumm Joshua T sold 7,837 shares
Chief Executive Officer @ $16.71 ($131.0K)
Sep 16, 2026 Insider
Brumm Joshua T sold 1,610 shares
Chief Executive Officer @ $17.90 ($28.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
CBIO Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 15, 2026
FDA
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial…
Oct 5, 2026
FDA
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and…
Sep 30, 2026
Short interest
Short Interest: CBIO up 40% to 4.8M shares
Settlement 2026-09-30 | Days to cover: 6.85 | ≈12.86% of shares outstanding (est.)
Sep 25, 2026
Press release
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage…
Sep 3, 2026
Press release
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage…

SecBot reports

13 filings · 3 press releases · 1 bullish · 2 bearish · 1 mixed · 9 neutral
All CBIO filing & press-release reports (16)